title: Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?
authors.affiliation: Uppsala University, Uppsala, Sweden.
authors.forename: Lars A
authors.initials: LA
authors.lastname: Påhlman
authors.affiliation: Universitätsklinikums Erlangen, Erlangen, Germany.
authors.forename: Werner M
authors.initials: WM
authors.lastname: Hohenberger
authors.affiliation: Universitätsklinikums Erlangen, Erlangen, Germany.
authors.forename: Klaus
authors.initials: K
authors.lastname: Matzel
authors.affiliation: Tokyo Medical and Dental University, Tokyo, Japan.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
authors.affiliation: St James's University Hospital, Leeds, United Kingdom.
authors.forename: Philip
authors.initials: P
authors.lastname: Quirke
authors.affiliation: Uppsala University, Uppsala, Sweden bengt.glimelius@igp.uu.se.
authors.forename: Bengt
authors.initials: B
authors.lastname: Glimelius
mesh_terms: D059186:Chemoradiotherapy, Adjuvant; D017024:Chemotherapy, Adjuvant; D003082:Colectomy; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D016896:Treatment Outcome